Novellus
Precision oncology company focused on developing BRAF inhibitor PLX-8394.
About
Novellus Ltd. is an Israeli clinical-stage biotechnology company focused on precision oncology. Their lead program, PLX-8394, is a BRAF inhibitor with a differentiated mechanistic profile, licensed from Plexxikon.
Similar companies
A cancer care navigation and support platform.
Shares Healthcare, Biotechnology
N-Power Medicine is a healthcare technology company transforming oncology drug development and community cancer patient care.
Shares Healthcare, Biotechnology
A leading children's research hospital dedicated to treating and curing childhood catastrophic diseases.
Shares Healthcare, Biotechnology
AI-powered spatial biology platform for precision medicine and drug development.
Shares Healthcare, Oncology
AI-driven drug discovery platform accelerating breakthrough scientific research.
Shares Healthcare, Oncology
Variantyx is a precision medicine company offering comprehensive genomic testing solutions for rare genetic disorders, reproductive health, and oncology.
Shares Healthcare, Oncology
Key facts
- Headquarters
- Jerusalem, Israel
- Total funding
- $57M (Series C)
- Business model
- B2B
Frequently asked
What does Novellus do?
The company utilizes a functional genomics platform called FACT to identify patient subpopulations likely to respond to specific drugs. Funds raised will support the clinical development of PLX-8394 for indications like BRAF fusions and certain BRAF-mutated gliomas, and expand their pipeline.
How much funding has Novellus raised?
Novellus has raised a total of $57M in funding. The most recent round on record is Series C.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Novellus
